| Active substance | empagliflozin |
| Holder | BOEHRINGER INGELHEIM Scomm |
| Status | Running |
| Indication | The use of Jardiance® in adults for the treatment of chronic kidney disease with an eGFR < 45 ml/min/1.73m² & uACR <200mg/g or with an eGFR ≥60 to <90 mL/min/1.73m2 in case of uACR ≥200 mg/g |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 16/01/2024 |